Teva Chosen As 'Bellwether' In US Price-Fixing Litigation
Case Involving Israeli Generics Giant Selected As Priority For Trial
Executive Summary
Litigation involving Teva has been selected as a “bellwether” case, making it a priority for trial as part of the ongoing US investigation into generic price-fixing.
You may also be interested in...
What’s Next? Five Things To Look Out For In August
Second-quarter earnings results from two of the Big Three – Teva and Mylan – hold much of the intrigue in August, while more competition in the nascent Avastin biosimilar market could materialize in Europe.
Glenmark Pushes Back On US Price-Fixing Charges
Glenmark has issued a forceful rebuttal over US price-fixing charges being pursued by the country’s Department of Justice covering drugs such as pravastatin.
Third Price-Fixing Lawsuit Filed In US
A third major price-fixing lawsuit has been filed in the US, naming over two dozen companies and ten individuals in allegations covering 80 generic presentations, focusing in particular on topical drugs.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Generics Bulletin?
Request a free trial today!
Register for our free email digests:
Register for our free email digests: